2'-FL and FOS Children Formula Composition for Digestive and Immune Support
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing infant formula compositions do not effectively address the synergistic benefits of 2′-fucosyllactose (2′-FL) and fructo-oligosaccharide (FOS) for enhancing digestive health and immune function in children, particularly in reducing digestive disorders and respiratory infections, especially in malnourished or at-risk children.
Innovation Solution
A children formula comprising 2′-fucosyllactose (2′-FL) and fructo-oligosaccharide (FOS) in specific ratios (1:(16-100) w/w, with FOS comprising Oligofructose and Inulin in a 1:1 ratio, combined with nutritional components, is formulated to reduce the risk of digestive disorders and respiratory infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing infant formula compositions use HMOs and prebiotics separately or in non-optimized ratios, then some digestive or immune benefits may be achieved, but the synergistic effects on reducing digestive disorders and respiratory infections are not fully realized
Solution Approach 1:
The patent specifies precise concentration ranges for 2'-FL (0.03-0.3 g/100g) and FOS (0.3-1.5 g/100g) in the supplementary composition, along with a weight ratio of 1:(16-100) between 2'-FL and FOS. These parameter optimizations enable synergistic effects that enhance immune function and reduce respiratory infections more effectively than non-optimized formulations.
Solution Approach 2:
The patent creates a composite supplementary composition combining 2'-fucosyllactose (2'-FL) and fructo-oligosaccharide (FOS) in specific ratios, along with vitamins and minerals. This composite formulation produces synergistic effects where the combination of components together provides greater immune enhancement and digestive health benefits than individual components alone.
2Reliability
If the children formula includes specific concentrations of 2'-FL and FOS with optimized ratios, then synergistic effects on digestive health and immune function are achieved, but the formulation complexity increases
Solution Approach 1:
The patent merges 2'-FL and FOS into a single supplementary composition that is integrated into the children formula. This composition includes 2'-FL at 0.03-0.3 g/100g, FOS at 0.3-1.5 g/100g, and various vitamins and minerals, creating a unified formulation that simplifies manufacturing while maintaining synergistic effects for digestive health and immune function.
3Object-affected harmful factors
If the formula is designed to reduce respiratory infections and digestive disorders through optimized oligosaccharide combinations, then health outcomes improve, but manufacturing precision requirements increase
Solution Approach 1:
The patent defines a specific weight ratio range of 1:(16-100) between 2'-FL and FOS, with 2'-FL at 0.03-0.3 g/100g and FOS at 0.3-1.5 g/100g. These parameter specifications enable manufacturers to control the oligosaccharide composition within defined ranges, ensuring consistent synergistic effects for reducing respiratory infections and digestive disorders while maintaining feasible manufacturing precision.
Data Source
AI summary
A process of manufacturing a children formula in a powder or solution form comprising the steps of mixing homogeneously nutritional components and a supplementary composition containing 2′-fucosyllactose (2′-FL) and fructo-oligosaccharide (FOS), such that when the children formula is fed to the child a chance of the child developing digestive disorders and respiratory infection is reduced, wherein a ratio between 2′-fucosyllactose (2′-FL) and fructo-oligosaccharide (FOS) is 1:(16-100) (w/w); in which the fructo-oligosaccharide (FOS) includes Oligofructose and Inulin, and a ratio between Oligofructose and Inulin is 1:1 (w/w).